Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need.

Rei Sakata, Pei-Yao Chang, Kyung Rim Sung, Tae-Woo Kim, Tsing-Hong Wang, Shamira A Perera, Louis B Cantor

Seminars in ophthalmology 2022 May 19

filter terms:

Topical prostaglandin analogs (PGAs) are widely approved and preferred first-line options for glaucoma and elevated intraocular pressure (IOP). However, prostaglandin-associated periorbitopathy syndrome (PAPS) is now a well-recognized clinical and cosmetic concern for patients receiving PGAs, especially during long-term and unilateral therapy. PGA-associated periocular changes occur in a substantial proportion of patients, with older patients (>60 years) at greater risk of clinical presentation. PAPS may hinder long-term management of glaucoma, including treatment adherence, ophthalmic surgery outcomes, and reliable IOP measurements. New therapeutic approaches may address this unmet clinical need. Omidenepag isopropyl (OMDI) is a novel, non-prostaglandin, selective EP2 receptor agonist in ongoing development, which provides a unique pharmacological mechanism of action. OMDI appears to provide IOP reductions comparable to PGAs, but without PAPS-related undesirable effects. OMDI may offer a suitable long-term option for patients who demonstrate decreased efficacy, or failure, of PGAs, plus patients with significant PAPS, while fulfilling international guidelines.

Citation

Rei Sakata, Pei-Yao Chang, Kyung Rim Sung, Tae-Woo Kim, Tsing-Hong Wang, Shamira A Perera, Louis B Cantor. Prostaglandin-associated periorbitopathy syndrome (PAPS): Addressing an unmet clinical need. Seminars in ophthalmology. 2022 May 19;37(4):447-454